Medifast outlines 2025 priorities with plans for $15M-$20M cost savings and new product expansions
Q4 2024 Management View CEO Dan Chard highlighted that 2024 was a transformative year for Medifast due to the increasing adoption of GLP-1 weight loss medications. The company is adapting to these ...
Mobix Labs targets 60% gross margin with strategic acquisitions in aerospace and defense
Q1 2025 Management View Fabian Battaglia, CEO, highlighted $3.17 million in Q1 2025 revenue, exceeding prior guidance and marking the fifth consecutive quarter of growth. He attributed this momentum ...